Cipla’s Revlimid Settlement Offers Date-Certain US Launch
Deal With Bristol Myers Squibb's Celgene Allows Initial ‘Limited’ Volumes
Cipla has become the latest generics firm to settle US patent litigation with Bristol Myers Squibb’s Celgene over its Revlimid blockbuster.
You may also be interested in...
Sun Pharma has become the latest ANDA sponsor to settle litigation with Celgene over Revlimid, shortly after Natco and partner Teva picked up the first ANDA approval for the blockbuster treatment for multiple myeloma.
Zydus Cadila has settled US patent litigation with Celgene over its proposed lenalidomide generic, marking the latest in a line of settlements over the Revlimid brand.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.